Medicovestor Signs Strategic Partnership with Sanyou Biopharmaceuticals to Advance Chemoimmunotherapy ADCs

• Medicovestor and Sanyou Biopharmaceuticals have formed a strategic partnership to jointly develop next-generation chemoimmunotherapy antibody-drug conjugates (ADCs).

• The collaboration combines Medicovestor’s ADoBind and ADoTope platforms with Sanyou’s AI-STAL technology for oncology and autoimmune indications.

Medicovestor, a biotechnology company based in New York, has entered into a strategic partnership with Sanyou Biopharmaceuticals, a Shanghai-based biologics specialist. The partnership, signed on 6 June, aims to jointly develop first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs) targeting cancer and autoimmune diseases.

The agreement integrates Medicovestor’s proprietary ADC platforms—ADoBind and ADoTope—with Sanyou’s AI-STAL (Artificial Intelligence-enabled Super Trillion Antibody Library) screening technology. The goal is to create next-generation therapies with higher efficacy at lower doses, leveraging both companies’ strengths in biologics research and development.

“This partnership reflects our commitment to redefining ADCs by integrating our differentiated ADC platforms with Sanyou’s world-class expertise in antibody development to incorporate immunotherapy into ADCs,” said Seah Lim, MD, PhD, Founder and CEO of Medicovestor.

David Lang, PhD, Founder and CEO of Sanyou Biopharmaceuticals, added: “We are excited to collaborate with Medicovestor to realize the promise of their highly innovative chemoimmunotherapy ADC platforms. By combining scientific excellence with execution capability, we aim to deliver transformative therapies that change patients’ lives.”

As part of the partnership, both companies will undertake joint research, technology transfer, and co-development of lead drug candidates. Milestones and candidate selections are expected to be announced in the coming quarters.